Zomaril

Zomaril

Iloperidone Psychiatry An antipsychotic for treating schizophrenia. See Schizophrenia, ZEUS.
Mentioned in ?
References in periodicals archive ?
The second placebo controlled efficacy study of Zomaril demonstrated positive results, and confirmed prior data regarding Zomaril's excellent safety profile.
The global trial, conducted by Novartis (NYSE:NVS), involved more than 600 patients at more than 40 centers throughout the US, Europe, Canada, Australia and South Africa and was designed to assess the ability of Zomaril to control safely and effectively the positive and negative symptoms in schizophrenia patients.
The results demonstrated that both dose levels of Zomaril used in the study achieved a highly statistically significant reduction in the symptoms of schizophrenia as assessed by the Brief Psychiatric Rating Scale.
With this recent progress, we are further encouraged that Zomaril may represent an important new option for patients with schizophrenia.
Our core development programs are advancing very well, with substantial progress this past quarter in our cancer immunotherapy, Spheramine, and Zomaril clinical programs.
Our Phase I/II clinical study of Spheramine for treatment of Parkinson's disease is progressing well, and the Zomaril Phase III program conducted by Novartis continues to advance well and on schedule.
We've considerably strengthened our balance sheet, which, when combined with our corporate partnership agreements for Zomaril and Spheramine, provides very significant resources for the continued growth and progress of our eight products in development.
The Zomaril Phase III program in schizophrenia is making excellent continued progress through Novartis, with exciting preliminary results from Phase III testing, and our CeaVac Phase III program in colorectal cancer is also proceeding very well.
The Phase III clinical program for Zomaril, which involves 3,300 patients at 208 sites in 24 countries worldwide, is moving ahead very well.